Navigating a complex drug development landscape, sponsors must rethink their approach to risk in study design and execution.
Mary Gunn, PhD, MBA
Advertisement
CEO of Emerald Clinical Trials
Articles by Mary Gunn, PhD, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Thermo Fisher, Lundbeck Announce New OpenAI Partnerships Advancing AI in Drug Development
2
Building Broader Investigator Networks to Advance Global Breast Cancer Research
3
dashClinical: Real-Time Participant Payments
4
ACT Brief: AI Expands Global Site Leadership as Ozempic Shows Potential to Reverse Biological Age
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
